Form 4 for EW Edwards Lifesciences
Accepted 2024-05-07 00:00:00 ET · period of report 2024-05-03 · accession 0001225208-24-005743 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-05-07 | 2024-05-06 | EW | Zovighian Bernard J | CEO, Dir | P - Purchase | $85.74 | +580.26 | 3,268 | +22% | +$49.8K |
| DM | 2024-05-07 | 2024-05-03+ | EW | Zovighian Bernard J | CEO, Dir | F - Tax | $85.23 | -4,245 | 46.8K | -8% | -$361.8K |
| D | 2024-05-07 | 2024-05-04 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | +6,265 | 50.6K | +14% | $0 |
| D | 2024-05-07 | 2024-05-04 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | -6,265 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-06 | P | A | 580.26 | $85.74 | 3,267.66 | I | — | — | (F2) Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator. |
| 2 | Common | Common Stock | 2024-05-03 | F | D | 527 | $85.06 | 44,288.90 | D 401(k) | — | — | |
| 3 | Common | Common Stock | 2024-05-04 | F | D | 3,718 | $85.25 | 46,835.90 | D | — | — | |
| 4 | Common | Common Stock | 2024-05-04 | M | A | 6,265 | $0.00 | 50,553.90 | D | — | — | (F1) On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. |
| 5 | Derivative | Performance Rights | 2024-05-04 | M | D | 6,265 | $0.00 | 0 | D | $0.00 · 2024-05-04 to — | 6,265 Common Stock | (F1) On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. |